Why the study?
Venous thromboembolism causes a high disease burden, prompting evaluation of unmet clinical needs and therapeutic strategies in three high-risk populations with suboptimal care: pregnant women, the elderly, and obese patients.
What are the unmet clinical needs in the prophylaxis and treatment of venous thromboembolism among pregnant, elderly, and obese patients?
What are the unmet clinical needs in the prophylaxis and treatment of venous thromboembolism among pregnant, elderly, and obese patients?
This review highlights significant gaps in VTE management guidelines for high-risk populations, emphasizing the need for tailored dosing and risk stratification in pregnant, elderly, and obese patients.
Answers are grounded in this paper and cite their sources.
Evidence gaps preclude confident VTE anticoagulation decisions in pregnancy, elderly, and obesity; leaves open need for targeted comparative trials.
BACKGROUND: Venous thromboembolism (VTE) accounts for an estimated 900,000 cases per year in the US alone and constitutes a considerable burden on healthcare systems across the globe. OBJECTIVE: To understand why the burden is so high, qualitative and quantitative research was carried out to gain insights from experts, guidelines and published studies on the unmet clinical needs and therapeutic strategies in VTE prevention and treatment in three populations identified as being at increased risk of VTE and in whom VTE prevention and treatment were regarded as suboptimal: pregnant women, the elderly and obese patients. METHODOLOGY: A gap analysis methodology was created to highlight unmet needs in VTE management and to discover the patient populations considered most at risk. A questionnaire was devised to guide qualitative interviews with 44 thrombosis and haemostasis experts, and a review of the literature on VTE in the specific patient groups from 2015 to 2017 was completed. This was followed by a Think Tank meeting where the results from the research were discussed. RESULTS: This review highlights the insights gained and examines in detail the unmet needs with regard to VTE risk-assessment tools, biomarkers, patient stratification methods, and anticoagulant and dosing regimens in pregnant women, the elderly and obese patients. CONCLUSIONS: Specifically, in pregnant women at high risk of VTE, low-molecular-weight heparin (LMWH) is the therapy of choice, but it remains unclear how to use anticoagulants when VTE risk is intermediate. In elderly patients, evaluation of the benefit of VTE prophylaxis against the bleeding risk is particularly important, and a head-to-head comparison of efficacy and safety of LMWH versus direct oral anticoagulants is needed. Finally, in obese patients, lack of guidance on anticoagulant dose adjustment to body weight has emerged as a major obstacle in effective prophylaxis and treatment of VTE.
No takes yet. Share an insight, caveat, or question.
Brenner et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: